Search

Niranjan Y Sardesai

from Blue Bell, PA
Age ~57
Get Report
Also known as:
Niranjan J Sardesai
Phone and address:
480 Mallard Cir, Blue Bell, PA 19422
(215) 540-0768
Related to:
Aditya N Sardesai, 22Arundhati SardesaiYeshwant Sardesai
Connected to:
David M Sardes, 49Rohit D Sardesai, 43Viraj Y Sardesai, 67Vikram R Sardeshpande, 47Alexandra Sardi, 30Gabriela Sardi, 35Gustavo J Sardi, 67Isabel Sardi, 50Alejandro J Sardinas, 31Amalia E Sardinas, 75

Niranjan Sardesai Phones & Addresses

  • 480 Mallard Cir, Blue Bell, PA 19422 (215) 540-0768
  • Rockville, MD
  • 102 Savory Ln, North Wales, PA 19454 (215) 540-0768
  • San Diego, CA
  • 1158 Main St, Lansdale, PA 19446
  • Cambridge, MA
  • Chicago, IL
  • Montgomery, PA
  • Pasadena, CA
  • Gaithersburg, MD
  • 480 Mallard Cir, Blue Bell, PA 19422

Work

Company: Inovio pharmaceuticals, inc. Jan 2012 to Feb 2019 Position: Chief operating officer at inovio pharmaceuticals, inc

Education

Degree: Master of Business Administration, Masters School / High School: The Wharton School 2004 to 2006 Specialities: Management, Finance

Skills

Biotechnology • R&D • Commercialization • Lifesciences • Vaccines • Clinical Development • Gmp • Assay Development • Medical Devices • Life Sciences • Product Development • Technology Transfer • Drug Delivery • Cancer • Drug Discovery • Biochemistry • Pharmaceutical Industry • Protein Chemistry • Biopharmaceuticals • Research and Development

Languages

Hindi • Marathi

Industries

Biotechnology

Resumes

Resumes

Niranjan Sardesai Photo 1

Co-Founder, President And Chief Executive Officer

View page
Location:
480 Mallard Cir, Blue Bell, PA 19422
Industry:
Biotechnology
Work:
Inovio Pharmaceuticals, Inc. Jan 2012 - Feb 2019
Chief Operating Officer at Inovio Pharmaceuticals, Inc
Geneos Therapeutics Jan 2012 - Feb 2019
Co-Founder, President and Chief Executive Officer
Inovio Pharmaceuticals Inc. Jun 2009 - Dec 2011
Senior Vp, Research and Development
Vgx Pharmaceuticals Nov 2007 - May 2009
Senior Vp, Research and Development
Vgx Pharmaceuticals Sep 2006 - Oct 2007
Vp, Product Development
Education:
The Wharton School 2004 - 2006
Master of Business Administration, Masters, Management, Finance Massachusetts Institute of Technology 1995 - 1997
Caltech 1989 - 1995
Indian Institute of Technology, Bombay 1984 - 1989
Master of Science, Masters, Chemistry
Skills:
Biotechnology
R&D
Commercialization
Lifesciences
Vaccines
Clinical Development
Gmp
Assay Development
Medical Devices
Life Sciences
Product Development
Technology Transfer
Drug Delivery
Cancer
Drug Discovery
Biochemistry
Pharmaceutical Industry
Protein Chemistry
Biopharmaceuticals
Research and Development
Languages:
Hindi
Marathi

Business Records

Name / Title
Company / Classification
Phones & Addresses
Niranjan Y. Sardesai
Chief Operating Officer, Svp Research And Development
Inovio Pharmaceuticals Inc.
Biotechnology · Mfg Vaccines and Other Immunization Products · Vaccines and Other Immunization Products
660 W Germantown Pike SUITE 110, Plymouth Meeting, PA 19462
1787 Sentry Pkwy W, Blue Bell, PA 19422
(267) 440-4200, (267) 440-4242

Publications

Us Patents

Smallpox Dna Vaccine And The Antigens Therein That Elicit An Immune Response

View page
US Patent:
8535687, Sep 17, 2013
Filed:
May 28, 2009
Appl. No.:
12/473634
Inventors:
Ruxandra Draghia-Akli - Brussels, BE
Jon Prigge - Spring TX, US
Niranjan Y. Sardesai - North Wales PA, US
David B. Weiner - Merion Station PA, US
Lauren A. Hirao - Philadelphia PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
Inovio Pharmaceuticals, Inc. - Blue Bell PA
International Classification:
A61K 39/275
A61K 39/12
A61K 39/00
C12Q 1/68
C12N 15/00
US Classification:
4242321, 4241861, 4242041, 424 92, 435 61, 4353201
Abstract:
The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of VACV EV antigens. Also, the present invention relates to methods of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising: injecting into tissue of said mammal said DNA vaccine.

Detection Of Mesothelin-/Megakaryocyte Potentiating Factor-Related Peptides For Assessment Of The Peritoneum And The Peritoneal Cavity

View page
US Patent:
20060014211, Jan 19, 2006
Filed:
Jan 21, 2005
Appl. No.:
11/040240
Inventors:
Daniel O'Shannessy - Schwenksville PA, US
Niranjan Sardesai - North Wales PA, US
Elizabeth Somers - Coatesville PA, US
Assignee:
Fujirebio Diagnostics, Inc. - Malvern PA
International Classification:
G01N 33/53
G01N 33/537
G01N 33/543
US Classification:
435007100, 435007500, 435007920
Abstract:
The invention relates to methods and kits for assessing occurrence in patient mesothelial fluid of peptides having amino acid sequences related to those of mesothelin, megakaryocyte potentiating factor, and other peptides that have been associated with occurrence in the serum of mesothelioma patients. The methods and kits can be used to monitor the biochemical or pathological status of a component of the corresponding mesothelial cavity in a patient, to predict development of such a pathological status in an otherwise asymptomatic patient, or to assess the efficacy of a therapeutic method.

Detection Of Urinary Mesothelin-/Megakaryocyte Potentiating Factor-Related Peptides For Assessment Of Mesothelioma

View page
US Patent:
20060014221, Jan 19, 2006
Filed:
Jan 21, 2005
Appl. No.:
11/040215
Inventors:
Daniel O'Shannessy - Limerick PA, US
Niranjan Sardesai - North Wales PA, US
Jennifer Bones - West Chester PA, US
Assignee:
Fujirebio Diagnostics, Inc. - Malvern PA
International Classification:
G01N 33/53
US Classification:
435007500, 435007920
Abstract:
The invention relates to methods and kits for assessing occurrence in patient urine of peptides having amino acid sequences related to those of mesothelin, megakaryocyte potentiating factor, and other peptides that have been associated with occurrence in the serum of mesothelioma patients. The methods and kits can be used to diagnose mesothelioma in a patient, to predict development of mesothelioma in an otherwise asymptomatic patient, or to assess the efficacy of a mesothelioma therapeutic method.

Novel Vaccines Against Multiple Subtypes Of Dengue Virus

View page
US Patent:
20100291144, Nov 18, 2010
Filed:
Jan 12, 2009
Appl. No.:
12/812268
Inventors:
Mathura P Ramanathan - Ardmore PA, US
Niranjan Y Sardesai - Blue Bell PA, US
Assignee:
VGX PHARMACEUTICALS, LLC - Blue Bell PA
International Classification:
A61K 39/21
A61K 39/12
A61K 39/145
C12N 15/63
US Classification:
4242081, 4242041, 4242091, 4353201
Abstract:
An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.

Methods And Apparatus For Conducting Multiple Measurements On A Sample

View page
US Patent:
20110105354, May 5, 2011
Filed:
Dec 23, 2010
Appl. No.:
12/977271
Inventors:
Eli N. Glezer - Chevy Chase MD, US
Kent Johnson - Bexley OH, US
Michael Tsionsky - Gaithersburg MD, US
John H. Kenten - Boyds MD, US
Jeff D. Debad - Gaithersburg MD, US
Robert M. Umek - Silver Spring MD, US
Paula Denney Eason - Germantown MD, US
Hans Biebuyck - Gaithersburg MD, US
Jacob N. Wohlstadter - Potomac MD, US
James Wilbur - Boyds MD, US
George Sigal - Rockville MD, US
Niranjan Y. Sardesai - North Wales PA, US
Assignee:
MESO SCALE TECHNOLOGIES, LLC - Gaithersburg MD
International Classification:
C40B 30/04
C40B 60/12
US Classification:
506 9, 506 39
Abstract:
Multiplexed test measurements are conducted using an assay module having a plurality of assay domains. In preferred embodiments, these measurements are conducted in assay modules having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence.

Dna Constructs Eliciting Immune Response Against Flavivirus And Effective Adjuvants

View page
US Patent:
20110262394, Oct 27, 2011
Filed:
Nov 17, 2009
Appl. No.:
13/129599
Inventors:
Mathura P. Ramanathan - Ardmore PA, US
Niranjan Y. Sardesai - Blue Bell PA, US
Assignee:
INOVIO PHARMACEUTICALS, INC. - Blue Bell PA
International Classification:
A61K 39/12
C07H 21/04
C07K 14/18
A61N 1/30
A61K 39/39
A61P 37/04
A61P 31/14
C12N 15/85
C07K 19/00
US Classification:
424 852, 4353201, 536 2372, 530350, 5303873, 4242181, 604 20
Abstract:
Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.

Foot And Mouth Disease Virus (Fmdv) Consensus Proteins, Coding Sequences Therefor And Vaccines Made Therefrom

View page
US Patent:
20120282217, Nov 8, 2012
Filed:
Nov 2, 2010
Appl. No.:
13/503828
Inventors:
David B. Weiner - Merion PA, US
Bernadette Ferraro - Philadelphia PA, US
Jian Yan - Havertown PA, US
Patricia A. Brown - Magnolia TX, US
Rodney A. Bowling - Austin TX, US
Douglas R. Kern - The Woodlands TX, US
Mathura P. Ramanathan - Ardmore PA, US
Niranjan Y. Sardesai - Blue Bell PA, US
Karuppiah Muthumani - Cherry Hill NJ, US
International Classification:
A61K 39/135
C12N 15/62
C12N 15/57
C12N 15/63
A61M 37/00
C07K 14/09
C07K 19/00
C12N 9/50
C12Q 1/70
G01N 33/569
C12N 15/42
A61K 38/20
US Classification:
424 852, 536 2372, 536 234, 536 232, 4353201, 4242161, 4241861, 530350, 435219, 530326, 530324, 435 5, 435 71, 530325, 604 20, 604 21
Abstract:
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.

Consensus Antigen Constructs And Vaccines Made Therefrom, And Methods Of Using The Same To Treat Malaria

View page
US Patent:
20130273112, Oct 17, 2013
Filed:
Sep 27, 2011
Appl. No.:
13/876148
Inventors:
David B. Weiner - Merion PA, US
Bernadette Ferraro - Philadelphia PA, US
Jian Yan - Havertown PA, US
Niranjan Y. Sardesai - Blue Bell PA, US
International Classification:
A61K 39/015
A61K 38/20
US Classification:
4242721, 536 237, 4353201, 536 235, 435 792, 536 2352
Abstract:
Provided herein is consensus amino acid sequences of (P.f.) proteins and their encoding sequences, as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against using the expression constructs provided herein.
Control profile
Niranjan Y Sardesai from Blue Bell, PA, age ~57 Get Report